There are a number of novel anticancer compounds already in clinical testing that make use of our TAP technology. Several of these target common cancers, such as HER2+ breast cancer, non-Hodgkin's lymphoma and multiple myeloma. Our TAP technology is poised to be the first antibody-drug conjugate (ADC) technology to be used for the treatment of widely occurring cancers.

Clinical-Stage Compound	Phase I	Phase II	Pivotal Phase II / Phase III
T-DM1
3rd-line HER2+ MBC
2nd-line HER2+ MBC
1st-line HER2+ MBC
Combination trials in MBC
Adjuvant trials under consideration
IMGN901
Multiple myeloma monotherapy
Multiple myeloma combination
Solid tumors
IMGN388* - solid tumors
SAR3419 - non-Hodgkin's lymphoma
BIIB015 - solid tumors
BT-062** - multiple myeloma
Earlier stage - multiple

Roche/Genentech Wholly-owned by ImmunoGen sanofi-aventis Biogen Idec Biotest MBC = metastatic breast cancer *Centocor has opt-in rights **ImmunoGen has opt-in rights